Category Archives: Cancer Research

The Importance of Gut Bacteria in the Spread of Pancreatic Cancer

The Importance of Gut Bacteria in the Spread of Pancreatic Cancer
The Importance of Gut Bacteria in the Spread of Pancreatic Cancer

Gut bacteria, or microbiome, include organisms that manufacture vitamins and promote healthy digestion and other functions. A study recently published in Cancer Discovery found that pathogenic gut bacteria can have a negative impact on pancreatic cancer treatment.

When Gut Bacteria Fights the Immune System

A research team at NYU School of Medicine conducted tests on both mice and humans with pancreatic ductal adenocarcinoma (PDA), a particularly aggressive form of pancreatic cancer. The scientists discovered that pathogenic, or “bad,” gut bacteria migrated to the pancreas, increasing bacterial presence by a thousand times.

Problems arise when this unbalanced mix of bacteria triggers a shutdown of immune cells, allowing cancer cells to multiply unchecked. Checkpoint inhibitors are a type of immunotherapy cancer treatment that reactivates immune cells, but they’re ineffective against the overwhelming amount of bacteria in the pancreas.

Using Antibiotics to Supplement Immunotherapy

When the researchers treated the mice with antibiotics, the amount of bacteria decreased enough to “flip the switch” on immune cells, thereby slowing cancer growth. In addition, checkpoint inhibitors were approximately three times more effective when used in conjunction with antibiotics.

Checkpoint inhibitors had previously failed to treat pancreatic cancer in clinical trials, so scientists are encouraged by these results. The team is now recruiting PDA patients to test the antibiotic-checkpoint inhibitor combo.

Issels®: Cancer Treatment Harnessing the Power of the Immune System

Our non-toxic immunotherapy programs focus on helping your body’s own immune system attack and kill cancer cells. These personally tailored treatments have fewer side effects and work to eliminate the causes that create tumors. Contact us for more information.

New Research: Programming DNA to Deliver Targeted Cancer Treatment

New Research: Programming DNA to Deliver Targeted Cancer Treatment
New Research: Programming DNA to Deliver Targeted Cancer Treatment

DNA carries the genetic information that makes you who you are. While DNA directs protein production by cells, scientists have discovered a way to turn DNA into an on/off switch for applications in cancer treatment.

DNA: A Protein Computer

In essence, DNA operates like a computer. Just as all digital data relies on various configurations of a two-component code, DNA uses different arrangements of a four-component code to determine which proteins need to be manufactured.

This similarity has given rise to a field called DNA computing. A research team at the University of Delaware recently engineered DNA strands with a code to create circuits programmed to open and close based on a specific logic.

Leveraging DNA Code

The next step was to make and purify the proteins that the scientists wanted to use. Once the custom-made DNA strands were received from the manufacturer, the proteins were attached to form protein-DNA conjugates.

When the DNA circuits were tested on both E. coli bacteria and human cells, the target proteins went through a series of stages just as they had been programmed to do.

Applications for Cancer Treatment

Once the DNA circuits proved to be successful, the UD team tested them with cancer prodrugs, which are inert until they’re metabolized into therapeutic form. The scientist designed DNA circuits to control the protein that triggers metabolism of the prodrug. Professor Wilfred Chen, lead author of the study, anticipates a future of “plug-and-play” DNA circuits.

Advanced Immunotherapy at Issels®

Our integrative cancer treatment programs often incorporate gene-targeted therapies and other methods that address a patient’s individual needs. Contact us to learn more.

Gene-Based Urine Tests Used for Bladder Cancer Discovery

Gene-Based Urine Tests Used for Bladder Cancer Discovery
Gene-Based Urine Tests Used for Bladder Cancer Discovery

What if you could determine your need for bladder cancer treatment from a routine urine sample, just like many other medical conditions? Scientists have recently developed a test that could make this a reality.

Using Gene-Based Testing for Early Cancer Detection

A team of researchers at Johns Hopkins Kimmel Cancer Center has been studying cancer genes to find more effective methods of early detection. Earlier this year, they announced a new blood test called CancerSEEK, which screens for eight different types of cancer, and PapSEEK, which screens for endometrial and ovarian cancers via cervical fluid samples.

In a study published in March, the team revealed the addition of another test called UroSEEK. Urine samples are analyzed for the presence of gene mutations or abnormal numbers of chromosomes, both of which are associated with bladder cancer and upper tract urothelial cancer (UTUC).

Identifying New Cancer Cases and Recurrences

During clinical studies involving 570 at-risk patients, UroSEEK had an 83 percent success rate identifying those who did develop bladder cancer. When UroSEEK was used in conjunction with cytology, the standard test for bladder cancer, accuracy rose to 95 percent.

According to Dr. David McConkey of the Johns Hopkins Greenburg Bladder Cancer Institute, bladder cancer has a high rate of recurrence. Another benefit of UroSEEK is that it can be used to effectively monitor patients who have already undergone treatment for bladder cancer.

Individually Created Cancer Treatment for Each Patient

At Issels®, we have been using gene-targeted therapies as one of the components of our integrative cancer treatment programs. Contact us for more information about our non-toxic protocols.

Robots May Soon be Performing Lung Laparoscopies for Cancer Detection

Robots May Soon be Performing Lung Laparoscopies for Cancer Detection
Robots May Soon be Performing Lung Laparoscopies for Cancer Detection

Robots are becoming increasingly entrenched in manufacturing, but do they have a place in cancer treatment? Earlier this year, the FDA approved a new robotic device for use in diagnosing lung cancer.

Robotics: Building Better Surgical Devices

As a surgical resident in the early 1908s, Fred Moll became convinced that there was a better way to perform procedures. After resigning his residency, Moll went to work creating high-tech medical devices.

Today Moll has become known for his invention of the $2 million da Vinci Surgical System, which is the top-selling surgical robot used in laparoscopic procedures. Surgeons operate the device using electronic hand controls and a video monitor.

But Moll is not content to rest on his laurels. He’s certain that medical robots will eventually be able to work autonomously, without relying on a surgeon’s control.

The Future of Robotic Surgery

On March 22, the FDA approved use of the Monarch Platform, which is the first step toward Moll’s ultimate vision. The new system includes a pair of arms as well as a long tube for doctors to steer a camera and other instruments inside the patient’s body.

At this point, FDA approval covers the Monarch Platform for use by a doctor to diagnose (and eventually treat) lung cancer. According to Moll, the Monarch will be able to drive itself in as few as 18 months from now.

Issels®: The Future of Cancer Treatment Is Here Today

While immunotherapy cancer treatment is a hot topic in the scientific community today, Issels® has had years of success with our individually developed programs. Visit our website to learn more.

Protein Biomarker Found for Liver Cancer That May Allow for Early Treatment

Protein Biomarker Found for Liver Cancer That May Allow for Early Treatment
Protein Biomarker Found for Liver Cancer That May Allow for Early Treatment

While some cancer rates have dropped, cases of liver cancer have actually tripled since the 1980s, with only 20 percent of patients surviving more than five years after diagnosis. Scientists are hoping to fight this trend with the discovery of a new protein biomarker that can lead to earlier cancer immunotherapy.

Dire Prognosis for Liver Cancer

The grim mortality rate for liver cancer is largely due to the fact that it’s usually diagnosed in late stages, by which point the liver has already sustained too much damage. A study recently published in the journal Nature describes findings that may enable earlier diagnosis.

Using Tumor Suppressors for More Accurate Diagnosis

Anti-cancer proteins known as tumor suppressors have the ability to check the rapid cell growth. Problems arise when the tumor suppressors in cancer cells fail to do their job.

A team at the University of Basel in Switzerland went in search of more effective tumor suppressors by testing a mouse model of liver cancer. The researchers examined more than 4,000 individual proteins in the diseased tissue and compared them to those in healthy tissue.

One protein called histidine phosphatase (LHPP) was found in healthy tissue but not in the tumor cells. Similar results were found when the team focused on LHPP in humans with liver cancer. Scientists are hopeful that LHPP can serve as a biomarker, allowing for earlier diagnosis and treatment.

Cancer Immunotherapy for Late-Stage and Therapy-Resistant Tumors

Issels® has a successful track record of helping patients with late-stage and therapy-resistant cancers achieve long-term remission. Visit our website to read and hear these stories from patients in their own words.

Highlighting a DNA-Based Lymphoma Treatment

Highlighting a DNA-Based Lymphoma Treatment
Highlighting a DNA-Based Lymphoma Treatment

One of the benefits of cancer immunotherapy is that it can offer options for patients when other treatments have failed. Doctors are having success with a new DNA-based treatment for certain forms of lymphoma.

CAR T-cell Therapy and Lymphoma

Chimeric antigen receptor T-cell therapy (or CAR T-cell therapy) may sound complicated, but the basic principle is simple. CAR T-cell therapy, like most types of cancer immunotherapy, works by boosting the ability of a patient’s own immune system to fight cancer.

With this procedure, T-cells are harvested from a patient and genetically engineered to produce surface receptors. The T-cells are then reintroduced into the patient’s system, where the receptors target a specific protein expressed by the lymphoma cells.

Dimas Padilla, a 44-year-old man from Orlando whose lymphoma had returned for a third time, was one of the 101 patients involved in a test of CAR T-cell therapy. Approximately half of the group experienced complete remission. Padilla himself has been tumor-free for 18 months.

Yescarta Wins FDA Approval

In October 2017, the FDA approved this treatment under the trade name Yescarta for use with certain types of B-cell lymphoma. This is only the second gene therapy to pass FDA approval, but at this point usage is restricted to patients who have unsuccessfully undergone at least two other forms of treatment.

Issels®: Personally Developed Cancer Immunotherapy for All Patients

No two cases of cancer are the same. Our non-toxic immunotherapy programs are created to meet each patient’s needs, even if previous treatments have failed. Contact us to learn how we have helped numerous patients achieve long-term remission.